1 / 15

Chemoprevention after polipectomy

Chemoprevention after polipectomy. Giuseppe Aprile Gianpiero Fasola Dipartimento di Oncologia Azienda Ospedaliero-Universitaria di Udine. Why is chemoprevention so complicated? Different studies with different endpoints, in different populations.

katoka
Télécharger la présentation

Chemoprevention after polipectomy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chemoprevention after polipectomy GiuseppeAprile Gianpiero Fasola Dipartimento di Oncologia Azienda Ospedaliero-Universitaria di Udine

  2. Why is chemoprevention so complicated? Different studies with different endpoints, in different populations Drug companies contributed to the land of confusion

  3. Candidate Agents • Aspirine • Other NSAIDs and COX-2 inhibitors • Difluoromethylornithine (DFMO) • Diet and Nutraceuticals • Antioxidants/Vitamins • Statins

  4. Systematic review of the available evidence (1970-2005) on the effectiveness of aspirin for the chemoprevention of colic adenomas, CRC, and CRC mortality, as well as potential harms.

  5. Bottom-line • Aspirina riduce il RR di adenoma colorettale in RCTs (RR 0.83, CI 0.7-0.95), studi caso-controllo (RR 0.75 CI 0.61-0.85), e in studi di coorte (RR 0.72, CI 0.61-0.85) • Se average-risk RR reduction nell’incidenza di adenoma 15-20%, possibliy higher se rischio maggiore • Contrastato il ruolo nella riduzione dell’incidenza di CRC (studi di coorte positivi, RCT negativi) • Dati insufficienti per mortalità • Benefici della chemioprevenzione più consistenti con uso di aspirina ad alte dosi per almeno 10 yrs • Possible harms (GI bleeding) require careful consideration

  6. Metanalisi di RCT sul ruolo dell’aspirina nella chemioprevenzione dell’adenoma colorettale Cole BF, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. JNCI 2009

  7. Is Adenoma Recurrence a Useful Surrogate for CRC Risk? Most small adenomatous polyps do not progress to malignancy Probability that a small adenoma contains high grade dysplasia/malignant changes is small (2%) Average transition time from small adenoma to invasive cancer > 10 years National Polyp Study. N Engl J Med,1993

  8. Number Needed to Treat (NNT) • Chemoprevention 10,000/15 = 700 treated for one cancer prevented 700 healthy people at risk for each person who benefits • Treatment of Disease (best case) 1 treated for one therapeutic effect 1 person at risk for each person who benefits

  9. Safety: Study Population Geriatric patient (>70 yrs, >85 yrs if surgeon) susceptibilities Severe drug toxicity Drug-drug interactions Potential for drug toxicity related to chronic administration Reduction of adenoma growth but dysplasia and CRCchanges may continue

  10. Selective COX-2 Inhibitors Celecoxib: 2001 FDA approved for adenomatous polyp prevention for individuals with FAP These data and retrospective data have led to extensive study of COX-2 inhibitors for sporadic adenomas as well

  11. Rofecoxib APPROVe Trial N=2,586 subjects Follow-up = 3,327 pt-years CV Adverse events (%) Placebo (2%) RR=1.0 25 mg QD (3.6%) RR=1.9 Celecoxib APC Trial N=2,035 subjects Follow-up = 2.8-3.1 years CV deaths (%) Placebo (1%); RR=1.0 200 mg BID (2.3%) RR=2.3 400 mg BID (3.4%) RR=3.4 Coxibs Cardiovascular Toxicity N Engl J Med. 2005;352:1071-80 N Engl J Med. 2005;352:1092-102

  12. Celecoxib, CRC prevention, safety issues Psaty and Potter, N Engl J Med 2006 Reviewed APC and PreSAP trials and concluded: • Celecoxib decreases adenoma formation • Celecoxib increases the risk of cardiovascular adverse events • The potential increase in CV event/mortality outweighs the projected decrease in colon cancer incidence

  13. Rofecoxib, CRC prevention, safety issues Kerr D et al. N Engl J Med 2007 Rofecoxib and cardiovascular adverse events in adjuvant treatment of CRC Reviewed VICTORe trial CV events, after a median treatment duration of 7.5 months: • Rofecoxib decreases adenoma formation • Rofecoxib significantly increases the risk of cardiovascular adverse events • RR for cardiovascular events 2.7 (CI 1.1-6.8)

  14. Do you see any improvement? 2000 2009

More Related